Holen Sie sich die Stockscreener-App
4.09
7.63%
0.29
Handel nachbörslich:
4.09
Schlusskurs vom Vortag:
$3.80
Offen:
$3.81
24-Stunden-Volumen:
111.56K
Relative Volume:
1.85
Marktkapitalisierung:
$124.68M
Einnahmen:
$4.01M
Nettoeinkommen (Verlust:
$-35.01M
KGV:
-4.3511
EPS:
-0.94
Netto-Cashflow:
$-24.53M
1W Leistung:
-9.11%
1M Leistung:
-46.25%
6M Leistung:
-20.43%
1J Leistung:
+2.25%
1-Tages-Spanne:
$3.72
$4.14
1-Wochen-Bereich:
$3.72
$4.6098
52-Wochen-Spanne:
$3.51
$9.96
Xbiotech Inc Stock (XBIT) Company Profile
Firmenname
Xbiotech Inc
Sektor
Branche
Telefon
512-386-2900
Adresse
5217 WINNEBAGO LANE, AUSTIN, TX
Vergleichen Sie XBIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
4.09 | 124.68M | 4.01M | -35.01M | -24.53M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-06-14 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-04-21 | Herabstufung | Noble Financial | Buy → Hold |
| 2016-06-28 | Bestätigt | Noble Financial | Buy |
Xbiotech Inc Aktie (XBIT) Neueste Nachrichten
XBiotech (NASDAQ:XBIT) Has Debt But No Earnings; Should You Worry? - Simply Wall St
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.SANA - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc.XBIT - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesCRBU - PR Newswire
XBiotech halts all rheumatology research after missing Phase II endpoints - Yahoo Finance
XBiotech setzt Rheumatologieprogramm aus - GlobeNewswire Inc.
Stock market news: YSX Tech. -28.67%, XBiotech -24.76% among biggest losers during mid day trading - Business Upturn
Another bump in the road for XBiotech and bermekimab - The Pharma Letter
Xbiotech Shares Hit 52-Week Low on Halted Rheumatology Program - MarketWatch
XBiotech Stock Hits 52-Week Low at $3.75 Amid Market Fluctuations - Investing.com
Stock market today: XBiotech -31.66%, Nvni Group -31.59% among biggest losers in early trading - Business Upturn
XBiotech trading resumes - Nasdaq
XBiotech Halts Rheumatology Clinical Program - MarketWatch
XBiotech Pauses Rheumatology program - GlobeNewswire
XBiotech Halts Rheumatology Program After Major Data Irregularities Found in Phase 2 Trial - StockTitan
Fmr LLC Has $224,000 Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
XBiotech Inc. (NASDAQ:XBIT) Stock Position Lifted by Charles Schwab Investment Management Inc. - Defense World
(XBIT) Proactive Strategies - Stock Traders Daily
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
12,157 Shares in XBiotech Inc. (NASDAQ:XBIT) Purchased by MetLife Investment Management LLC - Defense World
XBiotech (NASDAQ:XBIT) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD) Critical Analysis - Defense World
(XBIT) Investment Analysis and Advice - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Has $585,000 Position in XBiotech Inc. (NASDAQ:XBIT) - Defense World
Trend Tracker for (XBIT) - Stock Traders Daily
Empowered Funds LLC Cuts Stock Position in XBiotech Inc. (NASDAQ:XBIT) - Defense World
XBiotech (NASDAQ:XBIT) Stock Price Passes Below 50-Day Moving AverageHere's Why - MarketBeat
Cancer Cachexia Market Demand, Segments, And Growth to 2033 Helsinn, Aphios, Eli Lilly, XBiotech - openPR
How To Trade (XBIT) - Stock Traders Daily
XBiotech: Q3 Earnings Snapshot - New Haven Register
Transforming lives for those battling cancer with the speed & precision of AIRakovina Therapeutics (TSXV: RKV) | GCFF - NAI 500
XBiotech (NASDAQ:XBIT) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
XBiotech Inc.'s (NASDAQ:XBIT) 12% gain last week benefited both individual investors who own 49% as well as insiders - Simply Wall St
(XBIT) Technical Data - Stock Traders Daily
XBiotech (NASDAQ:XBIT) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
(XBIT) Technical Pivots with Risk Controls - Stock Traders Daily
Desmoplastic Small Round Cell Tumor Treatment Market Overall - openPR
XBiotech (NASDAQ:XBIT) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
How the (XBIT) price action is used to our Advantage - Stock Traders Daily
Enerflex Ltd. (NYSE:EFXT) Stake Increased by The Manufacturers Life Insurance Company - Defense World
Alopecia Areata Market Analysis, Size, Market Report 2024-2033 - WhaTech
76,460 Shares in XBiotech Inc. (NASDAQ:XBIT) Acquired by American Century Companies Inc. - Defense World
American Century Companies Inc. Acquires Shares of 76,460 XBiotech Inc. (NASDAQ:XBIT) - MarketBeat
Cancer Antigen Market Size Is Booming Worldwide with Share, Size, Top Key Players - Talented India
Rhumbline Advisers Has $103,000 Stock Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
Rhumbline Advisers Has $335,000 Stock Position in The First of Long Island Co. (NASDAQ:FLIC) - Defense World
Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World
XBiotech (NASDAQ:XBIT) vs. Harmony Biosciences (NASDAQ:HRMY) Financial Contrast - Defense World
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $6.63 - MarketBeat
Objective long/short (XBIT) Report - Stock Traders Daily
XBiotech (NASDAQ:XBIT) Shares Pass Above 50-Day Moving Average of $6.47 - MarketBeat
Finanzdaten der Xbiotech Inc-Aktie (XBIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):